Which breast cancer patients is suitable for Ixabepilone?

Ixabepilone is a microtubule inhibitor anticancer drug that is mainly used to treat patients with advanced or metastatic breast cancer, especially those whose disease has progressed after treatment with anthracyclines and taxanes. The drug was developed by Bristol-Myers Squibb in the United States and was approved for marketing by the U.S. FDA in 2007 under the trade name Ixempra. It is a type of epithelial cell inhibitor drug (epothilone B analog) with a unique structure. Its pharmacological mechanism is similar to paclitaxel, but it has higher affinity in molecular binding sites and drug stability, so it can maintain anti-tumor activity in some drug-resistant breast cancers.

From a clinical perspective, ixabepilone is suitable for patients who have developed resistance to conventional chemotherapy drugs (such as doxorubicin, paclitaxel, paclitaxel liposomes, etc.). Studies have shown that some metastatic breast cancers will overexpress P-glycoprotein during long-term medication, which will lead to increased excretion of taxane drugs and thus reduce the efficacy. However, ixabepilone is not a high-affinity substrate for P-glycoprotein, so it can effectively bypass the multidrug resistance mechanism and may still be effective in patients who have failed previous treatments.

In addition, ixabepilone is particularly suitable for patients**hormone receptor-negative (HR-) or triple-negative breast cancer (TNBC)** patients, who often respond poorly to conventional endocrine or targeted therapies. Ixabepilone can inhibit the division and mitosis process of cancer cells by directly acting on the microtubule structure, causing cancer cells to stay in the metaphase of division and inducing apoptosis. This mechanism of action determines its use in patients with different molecular subtypes of breast cancer.

In terms of treatment strategy, ixabepilone is often used as a single agent or in combination with capecitabine (Capecitabine) for patients who have progressed after previously receiving anthracycline and taxane chemotherapy. For patients with extensively metastatic or refractory disease, ixabepilone offers new treatment hope.

Reference materials:https://www.drugs.com/mtm/ixabepilone.html